Session » (2504–2523) Vasculitis – ANCA-Associated Poster III

Date: Tuesday, October 28, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 2519

A Disproportionality Analysis of FDA Adverse Event Reporting System (FAERS) Events for Avacopan

10:30AM-12:30PM: Abstract Number: 2505

Avacopan is Not Associated With An Increased Risk of Infection Compared to Glucocorticoids in Patients with ANCA-Associated Vasculitis

10:30AM-12:30PM: Abstract Number: 2513

Beyond Clinical trials in Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review of effectiveness and safety data derived from real-world evidence of Mepolizumab 300 mg

10:30AM-12:30PM: Abstract Number: 2522

Clinical Outcomes and Prognostic Impact of Cardiac and Cerebrovascular Involvement in Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Study

10:30AM-12:30PM: Abstract Number: 2514

Comparison of Demographics and Outcomes of Inpatient Hospitalization of Severe Asthma Patients with Eosinophilic Granulomatosis with Polyangitis. A Study on the National Inpatient Sample Database

10:30AM-12:30PM: Abstract Number: 2512

Contribution of the CALLY index at diagnosis to early prediction of all-cause mortality in patients with ANCA-associated vasculitis

10:30AM-12:30PM: Abstract Number: 2521

DANGER Score as Predictor of Mortality in ANCA-Associated Vasculitis with or without Glomerulonephritis: Data from the Almenara Vasculitis Cohort

10:30AM-12:30PM: Abstract Number: 2520

Evolution in Risk Stratification for Renal Outcomes in ANCA-Associated Vasculitides Using Established Scores and Histopathological Criteria in a Large European Cohort

10:30AM-12:30PM: Abstract Number: 2510

Impact of ANCA specificity on risk of severe infection occurrence in ANCA-associated vasculitis.

10:30AM-12:30PM: Abstract Number: 2518

Impact of psychiatric comorbidity on disease outcomes in ANCA-associated vasculitis: A multi-center retrospective cohort study

10:30AM-12:30PM: Abstract Number: 2516

Mortality Trends in Primary Systemic Vasculitis in the United States (1999–2023)

10:30AM-12:30PM: Abstract Number: 2508

Patient-Reported Outcomes in ANCA-Associated Vasculitis: Early Findings from a Prospective Real-World Cohort

10:30AM-12:30PM: Abstract Number: 2509

Predicting future relapse with proteomics in ANCA-Associated Vasculitis

10:30AM-12:30PM: Abstract Number: 2517

Predictors for Mortality in Patients Who Received Plasmapheresis for Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis

10:30AM-12:30PM: Abstract Number: 2523

Predictors of Glucocorticoid-Free Clinical Remission at Week 48 in Newly Diagnosed Microscopic Polyangiitis and Granulomatosis with Polyangiitis: from nation-wide registry in Japan (J-CANVAS)

10:30AM-12:30PM: Abstract Number: 2507

Reporting of infectious and hepatic adverse events with avacopan: insights from the World Health Organization pharmacovigilance database (VigiBase)

10:30AM-12:30PM: Abstract Number: 2515

The Association Between Neurologic Involvement and Cumulative Damage in ANCA-Associated Vasculitis

10:30AM-12:30PM: Abstract Number: 2511

The SHIPE index: A tertile-based approach to predict end-stage kidney disease in ANCA-associated vasculitis

10:30AM-12:30PM: Abstract Number: 2506

Timing, Management, and Outcomes of Venous Thromboembolic Events in ANCA-Associated Vasculitis: A Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 2504

Variables Associated with In-Hospital Mortality in Adult Eosinophilic Granulomatosis with Polyangiitis from the National Inpatient Sample Database 2017-2021

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].